Stock Scorecard
Stock Summary for Avalo Therapeutics Inc (AVTX) - $19.39 as of 7/31/2026 7:29:25 PM EST
Total Score
6 out of 30
Safety Score
37 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for AVTX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for AVTX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for AVTX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for AVTX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for AVTX (37 out of 100)
| Stock Price Rating (Max of 10) | 6 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 8 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for AVTX
Financial Details for AVTX
Company Overview |
|
|---|---|
| Ticker | AVTX |
| Company Name | Avalo Therapeutics Inc |
| Country | USA |
| Description | Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved diseases, particularly those related to immunological regulation. With a robust pipeline of proprietary drug candidates, Avalo is dedicated to addressing critical unmet medical needs in areas where effective treatments remain scarce. Leveraging in-depth insights into disease mechanisms alongside a rigorous clinical trial methodology, the company is well-positioned to achieve significant advancements in patient care. Through its patient-centric approach, Avalo not only seeks to improve therapeutic outcomes but also aims to make a substantial impact on the lives of those it serves, establishing itself as a noteworthy player in the biopharmaceutical landscape. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 3/31/2026 |
| Next Earnings Date | 8/6/2026 |
Stock Price History |
|
| Last Day Price | 19.39 |
| Price 4 Years Ago | 1,209.62 |
| Last Day Price Updated | 7/31/2026 7:29:25 PM EST |
| Last Day Volume | 935,221 |
| Average Daily Volume | 1,657,195 |
| 52-Week High | 24.27 |
| 52-Week Low | 7.87 |
| Last Price to 52 Week Low | 146.38% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 30.42 |
| Sector PE | 58.81 |
| 5-Year Average PE | -4.90 |
| Free Cash Flow Ratio | 40.40 |
| Industry Free Cash Flow Ratio | 13.69 |
| Sector Free Cash Flow Ratio | 31.51 |
| Current Ratio Most Recent Quarter | 7.66 |
| Total Cash Per Share | 0.48 |
| Book Value Per Share Most Recent Quarter | 2.77 |
| Price to Book Ratio | 15.12 |
| Industry Price to Book Ratio | 11.83 |
| Sector Price to Book Ratio | 9.48 |
| Price to Sales Ratio Twelve Trailing Months | 17,045.52 |
| Industry Price to Sales Ratio Twelve Trailing Months | 6.37 |
| Sector Price to Sales Ratio Twelve Trailing Months | 9.46 |
| Analyst Buy Ratings | 12 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 52,903,000 |
| Market Capitalization | 1,025,789,170 |
| Institutional Ownership | 76.72% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -122.78% |
| Reported EPS 12 Trailing Months | -5.42 |
| Reported EPS Past Year | -0.98 |
| Reported EPS Prior Year | -5.73 |
| Net Income Twelve Trailing Months | -84,740,000 |
| Net Income Past Year | -78,259,000 |
| Net Income Prior Year | -35,129,000 |
| Quarterly Revenue Growth YOY | -69.30% |
| 5-Year Revenue Growth | -61.19% |
| Operating Margin Twelve Trailing Months | -134,164.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 24,988,000 |
| Total Cash Past Year | 15,858,000 |
| Total Cash Prior Year | 134,546,000 |
| Net Cash Position Most Recent Quarter | 10,873,000 |
| Net Cash Position Past Year | -3,558,000 |
| Long Term Debt Past Year | 19,416,000 |
| Long Term Debt Prior Year | 19,416,000 |
| Total Debt Most Recent Quarter | 14,115,000 |
| Equity to Debt Ratio Past Year | 0.81 |
| Equity to Debt Ratio Most Recent Quarter | 0.83 |
| Total Stockholder Equity Past Year | 83,049,000 |
| Total Stockholder Equity Prior Year | 133,032,000 |
| Total Stockholder Equity Most Recent Quarter | 68,320,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -59,692,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.13 |
| Free Cash Flow Past Year | -51,458,000 |
| Free Cash Flow Prior Year | -49,056,000 |
Options |
|
| Put/Call Ratio | 0.03 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.47 |
| MACD Signal | 0.67 |
| 20-Day Bollinger Lower Band | 11.42 |
| 20-Day Bollinger Middle Band | 16.21 |
| 20-Day Bollinger Upper Band | 20.99 |
| Beta | 0.79 |
| RSI | 49.66 |
| 50-Day SMA | 15.36 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 7/31/2026 6:02:27 PM EST |